- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- What’s driving physicians to early retirement
- Why Tenet’s CEO says ASCs keep choosing USPI
- 12 recent hospital, health system president exits
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- 32 health systems spending $5B on cancer care
- Sanford, North Memorial planned combination adds to Minnesota healthcare deal wave
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- UT Austin launches Epic ahead of new academic medical center
- Ohio system names COO
- Buy, sell or fight: The new calculus of health system growth
- OpenAI’s growing healthcare footprint
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Why Cook County Health’s Medicaid coverage loss strategy is drawing attention
- Akron Children’s chosen for former Ohio college campus site
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- The growing war over Anthem’s out-of-network penalty policy
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Could ASCs help cardiology move past its ‘breaking point’?
- 3 programs expanding the anesthesia workforce in 2026
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- UVM Health targets $300M in cuts, outpatient overhaul amid $280M deficit
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- 5 data breaches, settlements impacting cardiology
- Maine hospital adds stroke prevention, cardiac imaging services
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- Trump plans to fire FDA chief Marty Makary: report
- Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Pennsylvania enacts dental faculty bill
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- New York expands behavioral health data access in EHRs
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- New Hampshire to receive $29.5M in Purdue opioid settlement
- Behavioral health leaders counter HHS ‘overprescribing’ narrative
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Alnylam rebuked by FDA over efficacy claims on Amvuttra website
- Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report
- FDA rolls out 1-day assessment pilot in bid to refocus inspection resources
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Novo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- FDA blocks publication of COVID, shingles vaccine safety studies: NYT
- Bayer diagnoses how to build trust in cell and gene therapies
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Hinge Health lifts 2026 outlook after strong Q1 as it expands to new conditions
- For nonprofit hospitals, pricey management consultants haven't yielded better performances: study
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Wellstar partners with BD to implement AI-driven medication management system
- Listen to the Latest ‘KFF Health News Minute’
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
- Surgeon Multitasking Increases Death Risk Of Organ Transplantees
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
The White House withdrew its nomination of Dr. Dave Weldon, a former Florida congressman, shortly before his scheduled appearance before the Senate Health, Education, Labor and Pensions Committee on Thursday. An anonymous White House official has said that Weldon didn't have the votes needed for confirmation by the Senate. Dr. Weldon wrote a four-page statement which was published by The Washington Post and The New York Times.
Big Pharma and the American Public Health Association were opposed to Dr. Weldon because he brought attention to research linking the MMR vaccine and IBD in children.
Jennifer Galardi of the Epoch Times wrote the most complete post mortem of Dr. Weldon's CDC nomination:
https://thefederalist.com/2025/03/14/scuttled-cdc-pick-slams-big-pharma-and-senators-on-its-payroll/
Scuttled CDC Pick Slams Big Pharma And Senators On Its Payroll
By Jennifer Galardi - March 14, 2025In a statement released on the day of his abruptly canceled confirmation hearing, Dr. Dave Weldon, President Trump’s initial nominee to lead the Centers for Disease Control and Prevention, said concerns that Big Pharma was behind the subversion were “probably true.”
“They are hands-down, the most powerful lobby organization in Washington DC giving millions of dollars to politicians on both sides of the aisle,” he wrote.
Weldon said that Wednesday evening, before the morning of his hearing before the Senate Health, Education, Labor, and Pensions (HELP) committee, he had received a call from a White House assistant telling him his nomination had been withdrawn due to a lack of affirmative votes.
According to Weldon’s statement, Health and Human Services Secretary Robert F. Kennedy Jr. told him Sen. Susan Collins of Maine suddenly “had reservations” about confirming him despite having “a very pleasant meeting” with Weldon previously.
“I can assume that the White House staff had my nomination withdrawn also because the Republican Chairman Dr. Bill Cassidy of Louisiana was also voting no,” Weldon wrote.
His claim that “politicians on both sides of the aisle” receive millions of dollars from pharmaceutical companies and lobbyists is undoubtedly true. Pharmaceutical companies spend almost $300 million on lobbying, far outpacing competitors such as the electronics manufacturing industry and insurance companies.
Why might Big Pharma have an interest in pressuring members of Congress to deny Weldon the job? You don’t have to look very far for the answer. Just review the hearings of every health official Trump has nominated to a cabinet position over the past month or so and count how many times “anti-vax” is said.
As a congressman from Florida 25 years ago, Weldon had the “temerity,” as he said in his letter, to question the pharmaceutical companies on what he called two “critical childhood vaccine safety issues.” Weldon said he, like Kennedy, had been approached by hundreds of parents insisting that vaccines had caused injuries, including autism, to their children. Back then, the concern was over a mercury-based preservative in the vaccines known as thimerosal, which is considered a neurotoxin.
Eventually the CDC and pharmaceutical companies agreed to remove thimerosal, though the preservative is still allowed in small amounts in some flu vaccines. The AI overview that pops up in a Google search claims “Extensive scientific research … has concluded that there is no credible evidence linking thimerosal to autism or other neurodevelopmental disorders.” Could it be because the major scientific and medical bodies were incentivized not to find credible evidence?
Weldon asserted that when the “CDC ended up publishing a research study claiming the mercury had done no harm,” there were “credible accusations that CDC had incorrectly manipulated the data to exonerate themselves.”
Weldon also took on the MMR (measles, mumps, rubella) shot, according to his letter, after coming across research by British pediatric gastroenterologist Andrew Wakefield suggesting that many children had suffered a form of inflammatory bowel disease upon taking the MMR shot.
Wakefield sent samples to Irish virologist John O’Leary, “who was able to show … that the inflammatory bowel disease biopsies in these children contained the vaccine strain measles viruses,” Weldon wrote. The theory was that it “also might have been affecting their central nervous system and causing the autistic features.”
Measles cases rose after parents became hesitant to give their kids the MMR shot, due to Wakefield and O’Leary’s research. Essentially, Weldon concluded, O’Leary was pressured to retract his findings and Wakefield lost his medical license.
Weldon believes these two objections killed his shot at being CDC director. He has forever been tarnished as an “anti-vaxxer” despite his insistence that he just wants solid, unbiased research done on the safety of vaccines.
“I have learned the hard way don’t mess with Pharma,” he wrote.
It raises the question: Can Big Pharma be beaten? Can Kennedy and his cohorts at the multiple health agencies really change the way people view health? The entire medical-industrial complex includes not only pharmaceutical companies, but hospitals, insurance companies, and even large food conglomerates, and it propels a good chunk of the American economy.
According to the Census Bureau’s 2019 American Community Survey (ACS), the healthcare industry employs 22 million workers, or 14 percent of the American workforce. Healthcare employment growth is projected to exceed the national average, even though access to primary care physicians is decreasing, suggesting growth in medical bureaucracy and administration rather than direct care providers.
People seem to forget that sickness is a very lucrative business. Pharmaceutical companies, more than any other industry in the medical establishment, are selling you a product. They pressure you to buy — and doctors to sell — their products through commercials, complete with musical dance numbers.
Pharmaceutical companies spend a lot of money researching why people might be hesitant to inject a vaccine into their body, so they can better shut down those concerns. However, according to a report in The Washington Post last week, the NIH will be terminating or limiting grants to fund research related to vaccine hesitancy. It’s a good first step to undoing the propaganda consistently forced down our throats when it comes to so-called healthcare.
Dave Weldon would have been an excellent choice to continue that trend at the CDC. Let’s hope President Trump will find someone equally courageous to follow in his footsteps — someone who can’t be purchased.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.













